Eisai’s Breakthrough Alzheimer’s Drug Wins Approval With Caveats
Eisai Co.’s breakthrough Alzheimer’s disease drug Leqembi gained full approval in the US. Yet, testing requirements and side effect warnings that may limit its use sent the company’s shares sliding.










